RTS Life Science Acquired by Entologi
Posted: 11 November 2010 | | No comments yet
ONE OF the UK’S fastest growing engineering groups, Entologi, is to buy leading life science automation company, RTS Life Science.
ONE OF the UK’S fastest growing engineering groups, Entologi, is to buy leading life science automation company, RTS Life Science.
ONE OF the UK’S fastest growing engineering groups, Entologi, is to buy leading life science automation company, RTS Life Science.
Carl Krajewski CEO Entologi with Gary Walsh MD RTS Life Science and Neville Buckley Chairman Entologi
Gary Walsh, RTS managing director, commented: “This acquisition represents a platform for expansion for us, whilst at the same time adding significantly to the Entologi Group.”
With a blue chip client list encompassing all ten of the top ten global pharmaceutical companies, RTS is a market leader in compound management and pharmaceutical testing solutions. The Company is also becoming a leading supplier in the rapidly expanding biobanking arena, with products encompassing both DNA storage and biological sample processing. RTS already uses technology and products from two other companies within the Entologi Group, HMK and Specific Environments.
RTS Life Science incorporates RTS’s specialist robotics and industrial technology group. Technical advances from this highly regarded team will benefit the whole Group, but will bring especial benefits to the life science business. The robotics and industrial technology group’s research is already central to several of RTS’s products, such as its Tube Auditor and its Biobanking product line.
With “world class engineering solutions” as our strapline”, said Entologi chairman, Neville Buckley, “the acquisition of a company whose ethos is already aligned with ours is ideal. Being part of a bigger Group should allow the RTS team the freedom to concentrate on exploiting our combined technology to bring new products to market while continuing to develop its long term customer relationships.”
RTS’s management team insists that it is very much “business as usual” for them. “I believe firmly that the company will benefit greatly from the backing of a Group growing both organically and by acquisition”, comments Walsh. “We will also be allowed the luxury of total focus on our core strengths without the distractions that inevitably accompany the management of a stand-alone Public Limited Company.”
